Skip to main content

Advertisement

Table 2 Multivariable Cox analysis for all-cause mortality

From: Prognostic impact of HbA1c variability on long-term outcomes in patients with heart failure and type 2 diabetes mellitus

  HR (model 1) 95% confidence interval P value HR (model 2) 95% confidence interval P value
HbA1c-SD (high, low) 1.649 1.288–2.110 < 0.001
HbA1c-CV (high, low) 1.558 1.216–1.997 < 0.001
E/e′ 1.069 1.015–1.125 0.011 1.063 1.010–1.119 0.019
LVEF (≥ 50, 40–49, < 40%) 1.159 1.003–1.340 0.045 1.178 1.019–1.362 0.021
Age 1.014 0.997–1.030 0.109 1.014 0.997–1.031 0.104
eGFR 0.990 0.977–1.003 0.142 0.989 0.976–1.003 0.115
ACEI/ARB 0.705 0.526–0.945 0.019 0.701 0.523–0.940 0.018
Beta-blocker 0.738 0.564–0.965 0.026 0.719 0.549–0.941 0.016
BNP (tertiles) 1.335 1.146–1.555 < 0.001 1.317 1.131–1.534 < 0.001
Ischemic HF 1.076 0.846–1.370 0.550 1.067 0.838–1.359 0.598
NYHA 1.103 0.994–1.287 0.217 1.019 0.949–1.296 0.191
Gender 1.098 0.849–1.421 0.475 1.111 0.859–1.438 0.423
Baseline HbA1c 1.045 0.850–1.285 0.674 1.036 0.843–1.274 0.733
Number of HbA1c measurements 1.034 0.974–1.098 0.277 1.030 0.970–1.094 0.332
HbA1c-mean 1.085 0.895–1.315 0.406 1.191 0.979–1.449 0.080
  1. HbA1c hemoglobin A1c, HbA1c-SD standard deviation of HbA1c, HbA1c-CV coefficient of variation of HbA1c, E/e′ mitral Doppler early velocity/mitral annular early velocity, LVEF left ventricular ejection fraction, eGFR estimated glomerular filtration rate, ACEI/ARB angiotensin converting enzyme inhibitor/angiotensin II receptor blocker, BNP B-type natriuretic peptides, MI myocardial infarction, NYHA New York Heart Association functional class